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Agenda
Development of inactivated polio vaccine from attenuated Sabin 
strains for clinical studies and technology-transfer purposes
1. Introduction Polio Vaccines
2. Sabin-IPV : Vaccine Development Project
3. Seedlots production
4. CTM (Clinical lots) production
5. Technology Transfer
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Polio - a disease which kills and debilitates
(photo NCG) Photo CDC Photo WHO Photo WHO
There is no cure for polio; it can only be prevented. 
Polio virus is highly infectious, and can invade the nervous system leading to paralysis.
One in every 200 infections leads to irreversible paralysis (usually in the legs).
08 June 2010 Sabin IPV Vaccine Development 4
Polio Vaccine Development
• Jonas Salk developed an injectable inactivated polio virus 
vaccine in 1952 (IPV)
• Albert Sabin developed the oral attenuated poliovirus vaccine 
in 1961 (OPV)
2009: 1606 polio cases worldwide
WHO anticipates polio eradication in 2013
Vaccination remains important in post-
eradication era
Photo WHO
MARCH, 29th 1954
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Worldwide Polio Incidence 2000 - 2009
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Sabin-IPV : Vaccine Development Project
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Sabin-IPV - Rationale
• Current tool for the WHO Polio Eradication program is: OPV
• Emergence and outbreaks of cVDPVs since 2000
• Therefore use of all OPV should be stopped after PE
• Risk: after PE developing countries will stop polio vaccination
• IPV production (using wild-type polio) is not feasible in 
developing countries because of containment risks
• Sabin-IPV appears feasible:
– OPV is currently produced in developing countries
– Lower risk of production facilities related polio outbreaks
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Proof-of-principle: Purifying OPV bulk
Monovalent bulk
(by BioFarma) 
Concentration
Purification
Inactivation
Monovalent pool
Proof-of-principle project 
(2007):
Preparation of purified
trivalent inactivated
Sabin-IPV
based on:
The current NVI Salk-IPV
production process
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Sabin-IPV project at NVI
Planned activities (2008 – 2011):
I. Clinical lot preparation & 
Prepare for Clinical studies and Licensing
II. Process optimization and dose reduction studies
for an affordable vaccine
III. Training and Tech Transfer :
– Generic workshop / training courses
– Strive for bilateral Tech Transfer agreements with DCVM
Kreeftenberg (2006) Biologicals; Kersten (1999) Vaccine
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Before CTM production : 
Lab-scale Process Development
• Multivariate Data Analysis (Salk-IPV production)
– For better process understanding
and future improvements
• Scale-down model (USP & DSP)
– Using DOE methods for future process improvements
ACF media; increased yields
• Set initial process specifications (Sabin-IPV production)
– MOI; virus culture temperature; SEC and IEX conditions
Thomassen et al 2010 Biotech Bioeng
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Multivariate data analysis
1. Find an easier way to represent data & its distribution
2. Develop models and find cause effect relations
Statistical approach stimulated by FDA guidance
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Current Salk-IPV production scheme
Vero cell
Media
Virus
Upstream processing
Downstream processing
Monovalent pool Trivalent bulk
IPV
DTP
Inactivation
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MVDA on IPV historical data
• Large and complex databases (> 60 runs in 10 years)
• Off-line & On-line measurements (> 75 in-process variables 
per step)
• Various process steps (cell culture / virus replication / DSP / 
inactivation)
• Different production scales
• Identify relevant parameters
• Derive operating ranges
• Improve process understanding
Thomassen et al 2010 Biotech Bioeng
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Current Salk-IPV production scheme
Vero cell
Media
Virus
Upstream processing
Downstream processing
Monovalent pool Trivalent bulk
IPV
DTP
Inactivation
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Performance analysis cell culture 2 x 350-L scale
Cluster 3:
Cytodex concentration,
glucose concentration,
Added glucose and pH
Represents experimental batches
Cluster 1:
DO, osmolarity
low glucose at start
Cluster 2:
High cell density;
low DO
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Conclusions of MVDA
• MVDA = powerfull tool to detect outliers and differences
• Robust & well-controlled process (CPP's run at set-point), however:
– Relatively large variation in the product quality attributes
– Therefore, currently model development was not possible
• Relevant parameters in cell & virus culture could be derived for product yield & 
quality, 
– like cell concentrations at culture start
Use of a scale-down model to explore extremes (design space) and derive
relations between CPP and CQA
CPP = Critical Process Parameters;  CQA = Critical Quality Attributes
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USP & DSP Scale-down model development
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DSP (SEC-step): Production & Lab-scale
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Sabin-IPV : Seedlot production
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Seedlot Generation
Source material:
• Type 1 : WHO / Behringwerke 1976 SO+1
• Type 2 : WHO / Behringwerke 1976 SO+1
• Type 3 : Institut Mérieux 1963 (457-Pfizer) RSO1
Master Seed Lots (3 types) : 10-L scale
Working Seed Lots (3 types): 350-L scale
Culture conditions :
MOI = 0.01 and T = 32.5°C for all types
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Milestone 1 :
Master (3x) & Working (3x) Seedlots made
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Sabin-IPV : CTM production
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Milestone 2 :
Monovalent Pools (6 lots) produced
Vero cell
Media
Virus
Upstream processing
Downstream processing
Monovalent pool
Inactivation
Process updated
where appropriate :
Clarification modernized
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Quality Control (QC)
• Selection of international release tests for production lots
(product should meet current IPV release criteria)
• Based on EP and WHO guidelines
• General assays (e.g. Protein, TOC, Sterility, etc.)
• Polio specific assays (e.g. D-ag, Virus titer, Rat Potency, etc.)
• Sabin specific assays (Neurovirulence)
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6 Monovalent Pools prepared : 2 lots per virus type (2 x 3 types = 6 lots) at 
700-L bioreactor production scale
Monovalent Pool QC-testing according to Bill-of-Testing in progress:
• Current status : conform requirements (e.g. Identity Vero cells & Sabin Polio virus, 
Mycoplasma, Extreneous agents, Sterility, Virus titer, D-antigen content, Inactivation, Endotoxins, 
Formalin, Bovine serum, Protein nitrogen, Residual DNA) 
Monovalent Pools (& Seedlots) QC-testing
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Formulation Development Conclusions
• On average 1 DU Sabin-IPV :
– Type 1 is 1.5 times more potent than 1 DU type 1 Salk-IPV
– Type 2 is 3 to 4 times less potent than 1 DU type 2 Salk-IPV
– Type 3 is comparable potent with 1 DU type 3 Salk-IPV
• Al(OH)3 adjuvation increases the Sabin-IPV potency 2 times
• Based on the relative potency Sabin-IPV could be formulated 
(expected needed dose) in :
 Plain (type 1 – 2 – 3) : 10 – 16 – 32 DU/shd
 + Al(OH)3 (type 1 – 2 – 3) : 5 – 8 – 16 DU/shd
For reference: Salk-IPV formulation is (type 1 – 2 – 3): 40 – 8 – 32 DU/shd
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Milestone 3 : Pre-clinical Tox study
Planned final product filling operations:
• Milestone 3 : Pre-clinical lots (safety) : 
Done, April 2010
• Phase I clinical lots : Q4 2010
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Sabin-IPV : Technology Transfer
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Technology Transfer
Starting from 2010 :
• IPV workshop on large-scale manufacturing planned in June 2010
• Setup Sabin-IPV production & QC-testing course for TT partners
• Transfer pilot-scale technology to selected DCVM partners for
implementation at their own facilities in 2011
Website launched : www.sabin-ipv.nl
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NVI pilot-plant facilities
150-L Bioreactor for Training (TT) purposes
Continuing a tradition …. Technology Transfer
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Conclusions
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